108 results about "Galectin-3" patented technology

Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials.

The present invention relates to novel compounds, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably a galectin 3.

The present invention relates to a method and a kit for diagnosing and/or predicting the occurrence of cancer or the risk of contracting a cancer by measuring the concentration of a cancer screening antigen(CSA) in blood, which changes before the occurrence of the cancer in a patient. The method of diagnosing or predicting the occurrence of cancer or the risk of contracting a cancer comprising the steps of: determining a concentration of galectin-3 in a blood sample by reacting the blood sample with a monoclonal antibody of the galectin-3; comparing the determined concentration of the galectin-3 with concentration of the galectin-3 in a blood sample of a normal human; and predicting the risk of contracting a cancer if the determined concentration is greater than the concentration of the galectin-3 in blood of the normal human.

Disclosed herein are methods for diagnosing or treating pregnancy related hypertensive disorders that include the use of a polypeptide or a nucleic acid encoding a polypeptide selected from the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehyrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.

There is provided a composition having an effective amount of N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier. Also provided by the present invention is a method of treating cancer by administering to a patient in need of such treatment an effective amount of N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier.

Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3. The novel compounds are defined by the general formula:

Described herein are materials and methods for predicting and monitoring a heart failure patient's physiological response to treatment with a statin. More specifically, the present invention relates to the endogenous protein galectin-3 and its use as a predictor of response to treatment with 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, or statins.

Methods for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-3 protein and/or a galectin-7 protein are provided. Pharmaceutical compositions comprising a pharmaceutically suitable carrier or diluent and as an active agent a galectin-3 protein and/or a galectin-7 protein are also provided.

The invention relates to a preparation method and application of an electrochemical sensor for detecting a blood concentration level of an insulin sensitivity reduction early diagnosis biomarker, namely galectin-3 (Gal-3), causing type II diabetes, and belongs to the technical field of electrochemical detection. The preparation method is characterized by comprising the following steps: respectively synthesizing an N-GNRs-Fe-MOFs@AuPNs sensor substrate modified nano composite material and an AuPt-MB nano composite signal material, enabling a detection antibody capable of being in specific binding to the Gal-3 to be mixed with the AuPt-MB composite material so as to prepare a biological signal probe; conjugating a Gal-3 specific capture antibody on a substrate platform modified by the N-GNRs-Fe-MOFs@AuPNs composite material so as to conveniently and specifically capture a target Gal-3; finally, performing specific binding on the Gal-3 as well as the detection antibody and the capture antibody, thereby obtaining the electrochemical sensor for detecting the blood concentration level of the Gal-3. The sensor is successfully used for detecting the Gal-3 in serum. The electrochemical sensor disclosed by the invention has the advantages of being high in sensitivity, high in specificity, rapid in detection and convenient. An early diagnostic basis is provided for insulin resistance causing the type II diabetes.

The invention discloses a detection kit for galectin-3 and a preparation method thereof. The detection kit comprises reagent I and reagent II which are independent of each other. Reagent I comprises a biobuffer, a coagulation accelerator, a preservative, a chelating agent, an inorganic salt and water; and reagent II comprises latex particles, the biobuffer, a surfactant, the preservative, a suspending agent, a blocking agent and water, wherein galectin-3 antibodies are coated by the latex particles. The latex particles with a particle size of 130 to 270nm are used for coating galectin-3 antibodies via chemical crosslinking, so that stability, sensitivity and relatively wide detection linear range of the detection kit are ensured. The detection kit possesses advantages such as excellent stability, high sensitivity and specificity, and convenient operation process; and is suitable for population and application.

The invention discloses a piece of colloidal gold test paper for rapidly and quantificationally detecting galectin-3. The colloidal gold test paper comprises a support gasket 5 and a nitrocellulose membrane 1 on the support gasket, wherein one end of the nitrocellulose membrane is connected with a water absorption pad 4, and the other end of the nitrocellulose membrane is connected with a conjugate gasket 2; the conjugate gasket is connected with a sample gasket 3; a first fixing part 7 is arranged under the other end of the sample gasket, and a second fixing part 6 is arranged above the other end of the sample gasket. The colloidal gold test paper is characterized in that a detection line 8 in the middle of the nitrocellulose membrane 1 is coated with a Gal-3 antibody; two control lines 9 are arranged at the two sides of the detection line, respectively; the conjugate gasket 2 is coated with a gold labeled Gal-3 monoclonal antibody or polyclonal antibody and a control line conjugate.

The present invention relates to materials and methods for monitoring and predicting a heart failure patient's physiological response to cardiac resynchronization therapy. More specifically, the present invention relates to the endogenous protein galectin-3 and its use in monitoring progression of disease in a patient undergoing cardiac resynchronization therapy, and as a predictor of response to cardiac resynchronization therapy.

The present invention provides a tumor screening marker that can be actually used in clinical practice to detect colorectal cancer, and a tumor progression marker that can complement CEA or CA19-9. Galectin-1 used as a tumor screening marker or a tumor progression marker for colorectal cancer. Galectin-3 used as a tumor screening marker. Galectin-4 used as a tumor progression marker, a tumor screening marker, or a prognostic prediction marker for colorectal cancer. A method of analyzing the galectin concentration in a collected blood sample using the galectin. A colorectal cancer marker detection kit comprising a detection antibody selected from the group consisting of a fluorescently labeled galectin-1 antibody, a fluorescently labeled galectin-3 antibody, and a fluorescently labeled galectin-4 antibody.